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differences in negative values could be the result of cul-
tural differences or due to small differences in the opera-
tionalization of TTO.
CONCLUSION: The differences in the value of health
between the European countries seem to be small. This
opens the door for a European tariff for the EQ-5D,
which might facilitate QALY-analysis in international tri-
als considerably.
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TO TRANSLATE OR TO ADAPT — 
WHAT DO THE QUESTIONS MEAN?
Doward LC, McKenna SP, Whalley D
Galen Research, Manchester, UK
OBJECTIVES: It is commonly assumed that the gold
standard method for producing new language versions of
patient-completed outcome measures is to translate using
back-translation. This paper will demonstrate that trans-
lation alone is insufficient and that back-translation is an
inherently flawed methodology.
METHODS: Literature review.
RESULTS: Back-translation fails to take account of the
complexity of nuances and meanings inherent in lan-
guage. While we might get back to where we started, it
does not imply that we have traveled by the appropriate
route. Back-translation can only succeed where straight-
forward semantic and conceptual equivalents exist in the
target language. In such a case, the method is likely to
have been an unnecessary expense. A further problem is
the reliance on bilinguals. Their social and health status
are likely to be higher than average, making them unrep-
resentative of the patient population. Thus, their use
should be restricted to producing a first draft translation.
This translation then needs to be assessed by people more
typical of the average patient participant, working in
their own language. The acceptability of this final version
also needs to be tested with relevant patients to confirm
comprehension and acceptability. However, adaptation
involves both the translation and psychometric testing of
an instrument for a new culture. It remains necessary to
test the psychometric properties of the translation for-
mally before it is used in a trial. The new version should
be shown to have acceptable reproducibility and con-
struct validity. Item response theory should also be ap-
plied to ensure that cultural response bias does not exist.
CONCLUSIONS: Back-translation by bilinguals cannot
guarantee that a translated questionnaire will be accept-
able to the target audience. Translation alone is not suffi-
cient to ensure that the new language version is suitable
for use in a clinical trial.
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Determining the best method for cost analysis of end-of-
life care regimens requires a systematic approach for con-
necting the research question being addressed with the
data requirements and analyses. There are several guiding
principles to direct this research, specifically in the areas
of sensitivity analysis, uncertainty, generalizability, and
measurement of efficiency such as cost-benefit or cost-
utility. There exists a body of literature in which disease-
specific or system-wide costing of health care is de-
scribed, but few apply to end-of-life care.
OBJECTIVE: To investigate, evaluate and present cost-
analysis methods through a synthesis of recently pub-
lished literature, and the implications of applying these
methods to ongoing clinical studies.
METHODS: Cost analyses include those acquired from
articles published in professional journals in the area of
cost, cost analysis and end-of-life care and applied to a
set of on-going clinical studies.
RESULTS: Based on a sample of nearly 30,000 cost stud-
ies in which few consider end-of-life care, at least eight
methods for examining costs of care are defined. On one
end of the spectrum is the micro-costing method in which
all personnel time, supplies, cost of facilities, pharmaceuti-
cals, lab expenses and all other patient services conducted
are tracked and costed using a variety of codes. On the
other end is the attributable costing method that uses ag-
gregate and average costs for inpatient and outpatient care
as well as for procedures and drugs associated with the
corresponding diagnosis and treatment. Only newly initi-
ated studies can feasibly employ micro costing. On-going
studies require abstracting from other methods.
CONCLUSIONS: In light of the national concern over
costs associated with end-of-life care, efforts are needed
to amalgamate guidelines and methodologies in this area
in order to provide a useful and accessible resource to
conduct meaningful cost-analysis research.
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OBJECTIVES: The aim of our research has been the valu-
ation of informal care. Informal care plays a substantial
role in the total care provided to patients with chronic dis-
eases. However, at this moment informal care is hardly in-
corporated in economic evaluations of health care. Espe-
cially the combination of the costs (time invested and
household expenditures) and effects (health-related quality
of life of informal care giving) is innovative.
METHODS: The data were collected by mailed question-
naires to primary informal caregivers in an evaluation of
Dutch integrated stroke service experiments, at two mo-
ments in time. The sample size is 217 informal caregivers
(two months after stroke) and 158 caregivers (six months
after stroke). We used a questionnaire including a range of
items on different informal care tasks. Health related quality
of life was measured with the EuroQol (EQ#64979; 5).
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RESULTS: Two months after stroke informal caregivers
spent 22.7 hours a week (mean) on a range of different care
tasks. Six months after stroke they spent 25.1 hours a week
(mean) on the same tasks. Their mean EQ-5 score is 0.836
(n  195) after two months and 0.816 (n  138) after six
months. After two months 40 percent reports pain and
other complaints and 25 percent reports anxiety. Six
months after stroke this is respective 45 percent and 25 per-
cent. Health related quality of life results and time invested
will be compared to the general population by sex and age.
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Current cost-effectiveness models of antibiotic efficacy
typically do not consider the variability in relative inci-
dence of infectious agents or the probability of species-
specific antibiotic resistance. A model that incorporates
this variability in incidence and resistance will more accu-
rately represent epidemiological variances and associated
differences in treatment costs across patient populations.
OBJECTIVES: To create a model of antibiotic efficacy
that generates population-specific cost-effectiveness ra-
tios by including incidence and resistance rates of infec-
tious agents and can be adjusted to reflect epidemiologi-
cal data specific to different geographic regions.
METHODS: We constructed a decision tree model that
represents a user-defined infection (i.e. acute exacerba-
tion of chronic bronchitis). This model considers the rela-
tive incidence of infectious agents (bacterial and non-
bacterial/viral), the incidence of resistance among the
bacteria agents, and antibiotic efficacy against each infec-
tious agent and level of resistance. The model can repre-
sent “all-or-none” resistance such as that associated with
beta-lactamase production, or varying degrees of suscep-
tibility associated with other methods of resistance. The
model can represent clinical or in vitro efficacy, depend-
ing on the source of the data. In the event of insufficient
data to populate the resistance branch, this branch can be
collapsed out of the tree. The model will then represent
antibiotic efficacy for all infectious agents included.
RESULTS: The model generates cost-effectiveness ratios
identifying conditions where the antibiotic of interest is
cost effective or cost saving versus other antibiotics. Ra-
tios for individual infectious agents and levels of resis-
tance also identify specific populations where the antibi-
otic of interest has an advantage.
CONCLUSIONS: This model can incorporate geographic
diversity of and resistance in bacterial populations to gen-
erate cost-effectiveness ratios specific to different epidemi-
ological and geographic populations.
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COST-EFFECTIVENESS OF TUBERCULOSIS 
PREVENTIVE THERAPY IN HIV-INFECTED 
PATIENTS: STUDY OF MISSING VARIABLES
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